CERVOMED INC (CRVO)
(Delayed Data from NSDQ)
$16.98 USD
+1.27 (8.08%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $16.89 -0.09 (-0.53%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Price, Consensus and EPS Surprise
CRVO 16.98 +1.27(8.08%)
Will CRVO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CRVO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for CRVO
CervoMed to Participate in Upcoming Investor Conferences
CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies
CervoMed’s Neflamapimod Shows Promise in DLB: A Buy Rating with a $65 Price Target
CervoMed Updates Investors on Business and Clinical Progress
Morgan Stanley Sticks to Their Buy Rating for CervoMed (CRVO)